Skip to content

Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • Mpox (Monkey Pox)
      • Smallpox
      • COVID-19
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us
March 2024

Controversies in Fibromyalgia: Tonmya* (TNX-102 SL) in Development for the Management of Fibromyalgia

Sign up for Email Alerts
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.

Cookie Notification
We use 1st and 3rd party cookies to enhance your experience of our website, save your preferences, and provide us with information on how you use our website. For more information, please refer to our Privacy Policy. By accessing or using our website, you consent to our use of cookies. You may opt out of the use of cookies by adjusting your browser settings.
ACCEPT